AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7037152 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin and cyclophosphamide (AC)
Number of subjects: 497
Study 7037152 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin, cyclophosphamide, and 5‐fluorouracil (FAC)
Number of subjects: 497
Study 7037152 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin followed by cyclophosphamide, vincristine, methotrexate, 5FU, and prednisone (A + COMFP)
Number of subjects: 497
Study 30821695 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthyMoms smartphone app
Number of subjects: 300
Study 30821695 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 300
Study 28143867 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant trastuzumab
Number of subjects: 114
Study 27506549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg once daily
Number of subjects: 328
Study 27506549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 23775924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 23775924 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 202
Study 23775924 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training
Number of subjects: 202
Study 23775924 — intervention group
Group type: COMPARATOR
Intervention: Cognitive treatment (control group)
Number of subjects: 202
Study 23775924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor training
Number of subjects: 202
Study 21984428 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated magnetic resonance therapy
Number of subjects: 0
Study 21984428 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnetic resonance therapy)
Number of subjects: 0
Study 20345019 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV seropositive children
Number of subjects: 1024
Study 20345019 — intervention group
Group type: COMPARATOR
Intervention: HIV seronegative children
Number of subjects: 1024
Study 20345019 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic ear discharge
Number of subjects: 1024
Study 20345019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenopathy
Number of subjects: 1024
Study 20345019 — intervention group
Group type: EXPERIMENTAL
Intervention: Clubbing
Number of subjects: 1024
Study 20345019 — intervention group
Group type: EXPERIMENTAL
Intervention: Marasmus
Number of subjects: 1024
Study 20345019 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepato-splenomegaly
Number of subjects: 1024
Study 20345019 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral candida
Number of subjects: 1024
Study 20345019 — intervention group
Group type: EXPERIMENTAL
Intervention: History of recurrent respiratory infection
Number of subjects: 1024
Study 20345019 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent fever
Number of subjects: 1024
Study 20345019 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent outpatient attendance or hospital admission
Number of subjects: 1024
Study 20345019 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent diarrhoea
Number of subjects: 1024
Study 20345019 — intervention group
Group type: EXPERIMENTAL
Intervention: Orphaning
Number of subjects: 1024
Study 20345019 — intervention group
Group type: EXPERIMENTAL
Intervention: Household contact with TB
Number of subjects: 1024
Study 20345019 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infected children
Number of subjects: 1024
Study 17366745 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet B7 (once daily sustained release tablets of aceclofenac)
Number of subjects: 0
Study 17366745 — intervention group
Group type: COMPARATOR
Intervention: Marketed product (control)
Number of subjects: 0
Study 17366745 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet B7
Number of subjects: 0
Study 15117041 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride (KCl)
Number of subjects: 61
Study 15117041 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium sodium citrate (K Na citrate)
Number of subjects: 61
Study 15117041 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium glycine (Mg glycine)
Number of subjects: 61
Study 15117041 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium magnesium citrate (K Mg citrate)
Number of subjects: 61
Study 14564870 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 20
Study 14564870 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 20
Study 14564870 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 20
Study 9039605 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium chelate-enhanced dynamic MR imaging
Number of subjects: 40
Study 7951087 — intervention group
Group type: EXPERIMENTAL
Intervention: Na/K/ATPase activity in patients with asthma and COPD
Number of subjects: 57
Study 7951087 — intervention group
Group type: EXPERIMENTAL
Intervention: Na/K/2Cl-cotransport activity in patients with asthma and COPD
Number of subjects: 57
Study 7951087 — intervention group
Group type: EXPERIMENTAL
Intervention: Na/K/ATPase activity
Number of subjects: 57
Study 7951087 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 healthy subjects)
Number of subjects: 57
Study 2889522 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 treatment group
Number of subjects: 382
Study 2889522 — intervention group
Group type: COMPARATOR
Intervention: Control treatment group
Number of subjects: 382
Study 31425459 — intervention group
Group type: EXPERIMENTAL
Intervention: Precooling (cold-water immersion for 15 minutes at 10.1 ± 0.3° C)
Number of subjects: 12
Study 31425459 — intervention group
Group type: COMPARATOR
Intervention: Control (no precooling)
Number of subjects: 12
Study 29411232 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients
Number of subjects: 309
Study 29411232 — intervention group
Group type: COMPARATOR
Intervention: Non-African American patients
Number of subjects: 309
Study 27740639 — intervention group
Group type: EXPERIMENTAL
Intervention: Short dental implants (5.5 or 7 mm)
Number of subjects: 82
Study 27740639 — intervention group
Group type: COMPARATOR
Intervention: Standard dental implants (10 or 12 mm)
Number of subjects: 82
Study 25287828 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 416
Study 25287828 — intervention group
Group type: COMPARATOR
Intervention: ECX
Number of subjects: 416
Study 22827974 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial telephone counseling intervention
Number of subjects: 22
Study 20346518 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg daily for 12 weeks
Number of subjects: 0
Study 20346518 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks followed by Escitalopram 10 mg daily for 12 weeks
Number of subjects: 0
Study 18656769 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg/kg for 10 minutes, followed by 0.5 microg kg(‐1) h(‐1))
Number of subjects: 40
Study 18656769 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 40
Study 16247191 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylate intolerance evaluation
Number of subjects: 0
Study 16247191 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic, diagnostic, and therapeutic options
Number of subjects: 0
Study 12544629 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive strength training (3 times weekly, 2 sets of 6-8 repetitions at 70-80% of one repetition maximum)
Number of subjects: 140
Study 12544629 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted squats
Number of subjects: 140
Study 12544629 — intervention group
Group type: EXPERIMENTAL
Intervention: Back extension
Number of subjects: 140
Study 12544629 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted march exercise
Number of subjects: 140
Study 10364860 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% in oxygen with rocuronium 0.3 mg.kg-1
Number of subjects: 140
Study 10364860 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% in oxygen with rocuronium 0.45 mg.kg-1
Number of subjects: 140
Study 10364860 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% in oxygen with rocuronium 0.6 mg.kg-1
Number of subjects: 140
Study 10364860 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2-3 mg.kg-1 with rocuronium 0.3 mg.kg-1
Number of subjects: 140
Study 10364860 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2-3 mg.kg-1 with rocuronium 0.45 mg.kg-1
Number of subjects: 140
Study 10364860 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2-3 mg.kg-1 with rocuronium 0.6 mg.kg-1
Number of subjects: 140
Study 10364860 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% in oxygen without muscle relaxant
Number of subjects: 140
Study 10364860 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2-3 mg.kg-1 without muscle relaxant
Number of subjects: 140
Study 8659554 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive long-term management program emphasizing inhaled corticosteroids and patient education (beclomethasone with a spacer, inhaled albuterol as needed, crisis prednisone).
Number of subjects: 39
Study 8659554 — intervention group
Group type: COMPARATOR
Intervention: Usual care from local physicians (Control group).
Number of subjects: 39
Study 8659554 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive long-term management program emphasizing inhaled corticosteroids and patient education.
Number of subjects: 39
Study 2071733 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) with home practice and application instructions
Number of subjects: 33
Study 2071733 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR) without home practice
Number of subjects: 33
Study 2071733 — intervention group
Group type: COMPARATOR
Intervention: Symptom monitoring group
Number of subjects: 33
Study 6362702 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.25 mg
Number of subjects: 0
Study 6362702 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.50 mg
Number of subjects: 0
Study 6362702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6362702 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.50 mg and Flunitrazepam 2.0 mg
Number of subjects: 0
Study 6362702 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam
Number of subjects: 0
Study 31075246 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 300
Study 31075246 — intervention group
Group type: COMPARATOR
Intervention: Buccal misoprostol
Number of subjects: 300
Study 30247961 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (Dru Yoga, once a week for 12 weeks)
Number of subjects: 83
Study 30247961 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC only)
Number of subjects: 83
Study 27423107 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% tofacitinib ointment twice daily
Number of subjects: 69
Study 27423107 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment twice daily
Number of subjects: 69
Study 24919385 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclizine (25 mg)
Number of subjects: 20
Study 24919385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate (40 mg) combined with Cinnarizine (25 mg)
Number of subjects: 20
Study 24919385 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (25 mg) combined with d-Amphetamine (10 mg)
Number of subjects: 20
Study 24919385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22132997 — intervention group
Group type: COMPARATOR
Intervention: Citrate-based anticoagulation (group C)
Number of subjects: 90
Study 22132997 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and low-dose citrate (group H)
Number of subjects: 90
Study 19913418 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative lymphoscintigraphy
Number of subjects: 117
Study 19913418 — intervention group
Group type: COMPARATOR
Intervention: No pre-operative lymphoscintigraphy
Number of subjects: 117
Study 17397097 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (50 mg)
Number of subjects: 84
Study 17397097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine high (1500-1800 mg)
Number of subjects: 84
Study 17397097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine low (600-900 mg)
Number of subjects: 84
Study 15911190 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based booklet
Number of subjects: 421
Study 15911190 — intervention group
Group type: COMPARATOR
Intervention: Leaflet
Number of subjects: 421
Study 15911190 — intervention group
Group type: COMPARATOR
Intervention: Video
Number of subjects: 421
Study 12576262 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital and repeated antenatal corticosteroids
Number of subjects: 299
Study 10384064 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of terbutaline
Number of subjects: 26
Study 10384064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8680672 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 24
Study 8680672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1986440 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (nifedipine SR + atenolol)
Number of subjects: 28
Study 1986440 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine SR
Number of subjects: 28
Study 1986440 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 28
Study 6833040 — intervention group
Group type: EXPERIMENTAL
Intervention: One-arm handgrip (HG)
Number of subjects: 12
Study 6833040 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-leg extension (LE)
Number of subjects: 12
Study 6833040 — intervention group
Group type: EXPERIMENTAL
Intervention: Dead-lift (DL)
Number of subjects: 12
Study 30243187 — intervention group
Group type: EXPERIMENTAL
Intervention: Early anticoagulation treatment
Number of subjects: 0
Study 30243187 — intervention group
Group type: EXPERIMENTAL
Intervention: Location of initial infarction (PCI vs ACI)
Number of subjects: 0
Study 28577938 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 675
Study 28577938 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 675
Study 25761743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirarubicin combined with hyaluronic acid
Number of subjects: 127
Study 25761743 — intervention group
Group type: COMPARATOR
Intervention: Pirarubicin alone
Number of subjects: 127
Study 24107284 — intervention group
Group type: EXPERIMENTAL
Intervention: online hemodiafiltration (HDF)
Number of subjects: 28
Study 24107284 — intervention group
Group type: COMPARATOR
Intervention: high-flux hemodialysis (HD)
Number of subjects: 28
Study 20464170 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) three times a week during the initial four weeks of anti-TB treatment
Number of subjects: 20
Study 20464170 — intervention group
Group type: COMPARATOR
Intervention: Anti-TB drugs only (Control)
Number of subjects: 20
Study 20464170 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 20
Study 18788653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem tartrate 3.5 mg
Number of subjects: 82
Study 18788653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem tartrate 1.75 mg
Number of subjects: 82
Study 18788653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 17410952 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride (SnF2) dentifrice
Number of subjects: 14
Study 17410952 — intervention group
Group type: COMPARATOR
Intervention: Standard 0.243% sodium fluoride (NaF) dentifrice
Number of subjects: 14
Study 12712784 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 60
Study 12712784 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 60
Study 10714624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically activated shears (UAS)
Number of subjects: 36
Study 10714624 — intervention group
Group type: COMPARATOR
Intervention: Conventional method using ligatures
Number of subjects: 36
Study 10714624 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonically activated shears (UAS) and Conventional method
Number of subjects: 36
Study 8823496 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral NK611 at doses of 5, 10, and 20 mg/m2 on day 1, followed by a daily oral dose of 20 mg/m2 from day 4 to day 7 for a total of 85, 90, and 100 mg/m2.
Number of subjects: 21
Study 8823496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous NK611 (30-min infusion) at doses of 5, 10, and 20 mg/m2 on day 1.
Number of subjects: 21
Study 8823496 — intervention group
Group type: EXPERIMENTAL
Intervention: NK611 (oral and intravenous administration)
Number of subjects: 21
Study 8823496 — intervention group
Group type: EXPERIMENTAL
Intervention: NK611
Number of subjects: 21
Study 1335640 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (0, 1 and 2 months schedule)
Number of subjects: 104
Study 1335640 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (0, 1 and 6 months schedule)
Number of subjects: 104
Study 1335640 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine
Number of subjects: 104
Study 6094422 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg sultamicillin, 12-hourly (series I)
Number of subjects: 0
Study 6094422 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg sultamicillin, 8-hourly (series II)
Number of subjects: 0
Study 29489727 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency resistance training (HFRT, n = 11)
Number of subjects: 23
Study 29489727 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency resistance training (LFRT, n = 12)
Number of subjects: 23
Study 30596721 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in velocity (Δv) of 3 / 6 km/h
Number of subjects: 52
Study 30596721 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle pre-tension (tense / relaxed)
Number of subjects: 52
Study 30596721 — intervention group
Group type: COMPARATOR
Intervention: Seating position (driver / front seat passenger)
Number of subjects: 52
Study 30596721 — intervention group
Group type: COMPARATOR
Intervention: Safety belt usage
Number of subjects: 52
Study 27242220 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma cytokines (IL-2, IL-4)
Number of subjects: 15
Study 25155134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet system (SSTS) 15 mcg with a 20-minute lockout interval
Number of subjects: 357
Study 25155134 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia with morphine sulfate (IV PCA MS) 1 mg with a 6-minute lockout interval
Number of subjects: 357
Study 25155134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet system (SSTS)
Number of subjects: 357
Study 21594234 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sodium ascorbate (SA) + bleaching with 10% carbamide peroxide (CP) + restoration
Number of subjects: 0
Study 21594234 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) + sodium ascorbate (SA) + restoration
Number of subjects: 0
Study 21594234 — intervention group
Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 0
Study 21594234 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with 10% carbamide peroxide (CP) + restoration
Number of subjects: 0
Study 21594234 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with 35% hydrogen peroxide (HP) + restoration
Number of subjects: 0
Study 20658810 — intervention group
Group type: EXPERIMENTAL
Intervention: MST plus ARC
Number of subjects: 615
Study 20658810 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 615
Study 20658810 — intervention group
Group type: EXPERIMENTAL
Intervention: MST only
Number of subjects: 615
Study 20658810 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC only
Number of subjects: 615
Study 17457124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 8 mg/kg
Number of subjects: 98
Study 17457124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 17457124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4-8 mg/kg
Number of subjects: 98
Study 17457124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 98
Study 17457124 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 98
Study 15088991 — intervention group
Group type: EXPERIMENTAL
Intervention: High sex-hormone-binding globulin levels
Number of subjects: 21
Study 15088991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-hormone-binding globulin
Number of subjects: 21
Study 15088991 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with vertebral fractures
Number of subjects: 21
Study 15088991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-hormone-binding globulin, total and free testosterone, and estradiol
Number of subjects: 21
Study 12532597 — intervention group
Group type: EXPERIMENTAL
Intervention: ximedon-electrophoresis
Number of subjects: 56
Study 9704236 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic carbohydrate diet
Number of subjects: 26
Study 9704236 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic carbohydrate diet
Number of subjects: 26
Study 7807484 — intervention group
Group type: EXPERIMENTAL
Intervention: Single, 1-g dose of cefazolin before clamping of the cord
Number of subjects: 307
Study 7807484 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 307
Study 2534552 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% azelaic acid cream
Number of subjects: 92
Study 2534552 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 92
Study 2534552 — intervention group
Group type: COMPARATOR
Intervention: 0.05% tretinoin cream
Number of subjects: 92
Study 1011957 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 49% Vo2max
Number of subjects: 6